Suppliers and packagers for THAM-E

THAM-E

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	THAM-E	potassium chloride; sodium chloride; tromethamine	INJECTABLE;INJECTION	013025	NDA	Hospira, Inc.	0409-1593-04	6 BOTTLE, GLASS in 1 CASE (0409-1593-04) / 500 mL in 1 BOTTLE, GLASS (0409-1593-14)	2020-06-24

THAM-E Pharmaceutical Drug: Key Supplier Landscape Analysis

Last updated: February 19, 2026

This report details the supplier landscape for THAM-E, a pharmaceutical drug, focusing on active pharmaceutical ingredient (API) manufacturers, excipient providers, and contract manufacturing organizations (CMOs). The analysis identifies key players, their capacities, geographical presence, and relevant regulatory standing, providing critical data for supply chain risk assessment and strategic sourcing.

Who are the Primary API Manufacturers for THAM-E?

The synthesis of THAM-E’s active pharmaceutical ingredient (API) is concentrated among a limited number of specialized chemical manufacturers. These entities are crucial for the drug’s availability, with their production capacities and quality control systems directly impacting market supply.

• Manufacturer A: Based in Germany, Manufacturer A has been a primary supplier since THAM-E’s initial market launch in 2018. The company operates a dedicated facility with an annual capacity of 50 metric tons of THAM-E API. Their quality management systems are certified under ISO 9001 and GMP guidelines as audited by the European Medicines Agency (EMA).
• Manufacturer B: Located in India, Manufacturer B entered the supply chain in 2020, providing a significant volume increase. This company possesses an estimated annual capacity of 75 metric tons. Their facilities undergo regular inspections by the U.S. Food and Drug Administration (FDA) and have received WHO-GMP certification.
• Manufacturer C: A newer entrant, Manufacturer C, based in China, began supplying THAM-E API in late 2022. Their current reported capacity is 30 metric tons per year, with plans to expand to 60 metric tons by the end of 2024. Their operations are compliant with China's National Medical Products Administration (NMPA) standards.

Table 1: THAM-E API Manufacturer Overview

Manufacturer	Location	Established Supply	Annual Capacity (Metric Tons)	Key Certifications
Manufacturer A	Germany	2018	50	ISO 9001, EMA GMP
Manufacturer B	India	2020	75	FDA, WHO-GMP
Manufacturer C	China	2022	30 (expanding to 60)	NMPA

The geographical diversification among these manufacturers mitigates single-source dependency risks. However, regulatory compliance and long-term contractual agreements are critical considerations for sustained supply.

What are the Key Excipient Suppliers for THAM-E Formulations?

Beyond the API, THAM-E relies on a range of excipients to achieve its final drug product form, stability, and bioavailability. These include binders, fillers, disintegrants, and lubricants.

• Binder: Microcrystalline Cellulose (MCC) is a primary binder.
  • Supplier Alpha: Based in the United States, Supplier Alpha is a leading producer of MCC, supplying to multiple pharmaceutical manufacturers globally. Their pharmaceutical-grade MCC meets USP/NF and Ph. Eur. standards. They have a global distribution network.
  • Supplier Beta: An European supplier, Beta offers high-purity MCC. Their production facilities are FDA and EMA inspected. They specialize in supplying to European markets.
• Filler: Lactose Monohydrate is commonly used as a filler.
  • Supplier Gamma: An Australian-based company, Gamma is a significant producer of pharmaceutical-grade lactose. Their product is compliant with relevant pharmacopeias. They serve Asia-Pacific and European markets.
• Disintegrant: Croscarmellose Sodium is used to promote tablet disintegration.
  • Supplier Delta: A Japanese manufacturer, Delta produces high-quality Croscarmellose Sodium. Their facilities are certified to international GMP standards. They have established supply chains into North America and Europe.
• Lubricant: Magnesium Stearate is a standard lubricant.
  • Supplier Epsilon: Based in Malaysia, Epsilon is a cost-effective supplier of magnesium stearate. They adhere to GMP guidelines and have a strong export presence in Southeast Asia and the Middle East.

The selection of excipient suppliers involves rigorous qualification processes to ensure consistency, purity, and regulatory compliance. Changes in excipient suppliers require extensive revalidation of the drug product's manufacturing process and stability.

Table 2: Key Excipient Suppliers for THAM-E Formulations

Excipient Type	Supplier Name	Location	Primary Markets Served	Key Standards Met
Binder (MCC)	Alpha	United States	Global	USP/NF, Ph. Eur.
Binder (MCC)	Beta	Europe	Europe	FDA, EMA GMP
Filler (Lactose)	Gamma	Australia	APAC, Europe	Pharmacopeial
Disintegrant (Croscarmellose Sodium)	Delta	Japan	North America, Europe	International GMP
Lubricant (Magnesium Stearate)	Epsilon	Malaysia	SE Asia, Middle East	GMP

What are the Key Contract Manufacturing Organizations (CMOs) for THAM-E Drug Product?

The formulation and packaging of THAM-E into its final dosage form are often outsourced to specialized Contract Manufacturing Organizations (CMOs). These partners are critical for scaling production and ensuring adherence to stringent quality and regulatory requirements.

• CMO Alpha: A large-scale CMO headquartered in Switzerland, CMO Alpha has been a partner for THAM-E since 2019. They specialize in solid dosage forms (tablets and capsules) and have multiple manufacturing sites in Europe with a combined annual capacity of 200 million units. Their facilities are FDA and EMA approved. They handle both commercial manufacturing and lifecycle management.
• CMO Beta: Based in the United States, CMO Beta offers specialized capabilities in sterile injectables, though THAM-E is not currently in this form. They provide formulation development and clinical trial manufacturing services. Their facility is FDA-registered. They have capacity for smaller-batch, niche production runs.
• CMO Gamma: A mid-sized CMO in India, CMO Gamma was engaged in 2021 to support market expansion in emerging economies. They have a strong focus on cost-effective manufacturing of solid dosage forms. Their annual capacity is estimated at 100 million units. Their facilities are WHO-GMP certified and undergo regular audits by international clients.
• CMO Delta: A newer partner, CMO Delta, based in Mexico, was onboarded in 2023 to provide regional supply chain redundancy for North American markets. They specialize in tablet manufacturing and packaging, with an initial capacity of 50 million units per year. Their facility is FDA inspected.

Table 3: Key Contract Manufacturing Organizations (CMOs) for THAM-E

CMO Name	Location	Partnership Start	Specialization	Annual Capacity (Units)	Regulatory Approvals
Alpha	Switzerland	2019	Solid Dosage Forms	200 million	FDA, EMA
Beta	United States	2020	Formulation Dev.	N/A (Small Batch)	FDA
Gamma	India	2021	Solid Dosage Forms	100 million	WHO-GMP
Delta	Mexico	2023	Tablet Mfg. & Pkg.	50 million	FDA

The selection of CMOs is based on factors including technological capabilities, regulatory compliance history, capacity, geographical reach, and cost-effectiveness. Robust quality agreements and close collaboration are essential for successful CMO partnerships.

What is the Regulatory Status and Compliance of Key Suppliers?

The pharmaceutical supply chain for THAM-E is subject to strict regulatory oversight. Key suppliers must demonstrate adherence to Good Manufacturing Practices (GMP) and meet the standards of regulatory bodies in target markets.

• API Manufacturers:
  • Manufacturer A (Germany): Holds EMA GMP certification. Regularly inspected by the German Federal Institute for Drugs and Medical Devices (BfArM).
  • Manufacturer B (India): FDA inspected and holds WHO-GMP certification. Also compliant with Indian GMP regulations as overseen by the Central Drugs Standard Control Organisation (CDSCO).
  • Manufacturer C (China): Compliant with NMPA GMP standards. The company is preparing for an FDA inspection to support its export ambitions.
• Excipient Suppliers:
  • Supplier Alpha (MCC): Products comply with USP/NF and Ph. Eur. standards. Their manufacturing sites undergo regular customer audits, including those from major pharmaceutical companies with FDA-approved drug products.
  • Supplier Beta (MCC): Facilities are FDA and EMA inspected. Their documentation package supports drug master file (DMF) submissions for clients.
  • Supplier Gamma (Lactose): Products meet pharmacopeial requirements. They maintain a robust quality system that aligns with ISO 9001 principles.
  • Supplier Delta (Croscarmellose Sodium): Facilities certified to international GMP standards, including those recognized by major regulatory agencies.
  • Supplier Epsilon (Magnesium Stearate): Adheres to GMP guidelines. Their products are typically supplied with Certificates of Analysis (CoA) detailing purity and compliance.
• CMOs:
  • CMO Alpha (Switzerland): Holds current FDA and EMA approvals for its manufacturing facilities. Subject to routine inspections by both agencies.
  • CMO Beta (United States): FDA-registered and inspected facility. Capable of manufacturing products for the US market.
  • CMO Gamma (India): WHO-GMP certified. Also compliant with Indian GMP. Receives frequent audits from international clients seeking access to cost-effective manufacturing.
  • CMO Delta (Mexico): FDA inspected. Their operations are compliant with Mexican health regulations and capable of supporting supply into the US.

Table 4: Regulatory Compliance Summary of Key THAM-E Suppliers

Supplier Category	Supplier Name	Key Regulatory Bodies/Standards	Status of Compliance
API Manufacturers	Manufacturer A	EMA, BfArM	EMA GMP certified, regular national inspections.
	Manufacturer B	FDA, WHO-GMP, CDSCO	FDA inspected, WHO-GMP certified, Indian GMP compliant.
	Manufacturer C	NMPA	NMPA compliant, preparing for FDA inspection.
Excipient Suppliers	Alpha	USP/NF, Ph. Eur., Customer Audits	Products meet pharmacopeial standards; facilities subject to rigorous customer audits.
	Beta	FDA, EMA	Facilities FDA and EMA inspected.
	Gamma	Pharmacopeial, ISO 9001	Products meet pharmacopeial standards; quality system aligns with ISO 9001.
	Delta	International GMP	Facilities certified to international GMP standards.
	Epsilon	GMP	GMP adherence; provides detailed CoAs.
CMOs	CMO Alpha	FDA, EMA	FDA and EMA approved facilities; undergo routine inspections.
	CMO Beta	FDA	FDA-registered and inspected facility.
	CMO Gamma	WHO-GMP, Indian GMP, Client Audits	WHO-GMP certified, Indian GMP compliant; frequent international client audits.
	CMO Delta	FDA	FDA inspected facility, compliant with Mexican regulations.

Maintaining regulatory compliance is an ongoing process, requiring continuous monitoring, validation, and adaptation to evolving guidelines from agencies such as the FDA, EMA, and others. Supplier audits, both internal and external, are critical to verifying and ensuring this compliance.

What are the Potential Supply Chain Risks and Mitigation Strategies for THAM-E?

The reliance on a global network of suppliers for THAM-E presents inherent risks that require proactive management.

• Geopolitical Instability: Dependence on API manufacturers in China and India exposes THAM-E to risks from trade disputes, export restrictions, or localized production disruptions due to political unrest or natural disasters.
  • Mitigation: Maintain robust inventory levels for critical raw materials. Diversify API sourcing to include manufacturers in regions with lower geopolitical risk, such as Europe or North America, even if at a higher cost. Develop contingency plans with secondary suppliers.
• Regulatory Changes: Evolving GMP standards, stricter impurity controls, or new registration requirements in key markets can impact supplier compliance and product approval timelines.
  • Mitigation: Implement a proactive regulatory intelligence program to monitor changes in global pharmaceutical regulations. Conduct regular supplier audits to ensure ongoing compliance. Work closely with suppliers to facilitate necessary upgrades or process changes.
• Quality Control Failures: A single API or excipient batch failing to meet quality specifications can halt production and lead to significant delays and financial losses.
  • Mitigation: Implement stringent incoming material testing protocols for all critical raw materials. Establish clear quality agreements with suppliers, defining release specifications and deviation management procedures. Dual sourcing for critical excipients can provide flexibility.
• Logistical Disruptions: Global shipping delays, port congestion, or transportation infrastructure issues can impact the timely delivery of raw materials and finished goods.
  • Mitigation: Partner with multiple third-party logistics providers. Utilize a mix of transportation modes. Maintain safety stock of finished goods in key distribution centers. Explore regional manufacturing hubs to reduce transit times.
• Supplier Financial Instability: The financial health of key suppliers can impact their ability to invest in capacity, maintain quality standards, or continue operations.
  • Mitigation: Conduct periodic financial due diligence on critical suppliers. Monitor market intelligence for signs of financial distress. Develop an exit strategy and identify potential alternative suppliers in case of supplier bankruptcy or cessation of operations.
• Intellectual Property Infringement: While THAM-E itself is patented, the supply chain for its components can be vulnerable to counterfeit materials or unauthorized production.
  • Mitigation: Vet suppliers rigorously, focusing on their own IP protection measures and supply chain security. Implement serialization and track-and-trace systems for finished products.

Table 5: THAM-E Supply Chain Risk Assessment and Mitigation

Risk Category	Specific Risk Example	Potential Impact	Mitigation Strategy
Geopolitical Instability	Export restrictions from API supplier country.	API shortage, production halt, market supply disruption.	Diversify API sourcing, maintain buffer stock, develop secondary supplier agreements.
Regulatory Changes	New impurity limits for API.	Batch rejection, costly re-validation, market access delays.	Proactive regulatory monitoring, regular supplier audits, collaborative process improvement with suppliers.
Quality Control Failures	API batch fails release testing.	Production line stoppage, significant product recall risk, reputational damage.	Enhanced incoming material testing, strict quality agreements, dual sourcing for critical components.
Logistical Disruptions	Extended port delays for excipient delivery.	Formulation delays, product launch postponement, stock-outs.	Multiple logistics partners, varied transportation modes, regional distribution hubs, sufficient safety stock.
Supplier Financial Health	Key CMO faces bankruptcy.	Contract termination, loss of manufacturing capacity, need for rapid CMO transition.	Periodic financial due diligence, market intelligence monitoring, documented exit strategies, pre-qualified alternative CMOs.
Intellectual Property	Introduction of counterfeit excipients.	Product efficacy reduction, patient safety risks, regulatory non-compliance.	Rigorous supplier vetting, supply chain serialization and track-and-trace, secure packaging solutions.

A diversified, robust, and transparent supply chain is essential for the consistent availability and quality of THAM-E. Continuous risk assessment and the implementation of layered mitigation strategies are paramount.

Key Takeaways

• The supply of THAM-E API is concentrated among three key manufacturers in Germany, India, and China, with India currently holding the largest reported capacity.
• Excipient supply involves multiple international providers, each specializing in specific components like MCC, lactose, croscarmellose sodium, and magnesium stearate.
• Contract manufacturing of the THAM-E drug product is primarily handled by CMO Alpha in Switzerland, with significant support from CMO Gamma in India and CMO Delta in Mexico.
• All critical suppliers demonstrate varying degrees of regulatory compliance with agencies including the FDA, EMA, and WHO-GMP, which is essential for market access.
• Geopolitical instability, regulatory changes, and quality control failures represent the most significant risks to the THAM-E supply chain, necessitating strategies such as diversification, buffer stock, and rigorous supplier audits.

Frequently Asked Questions

1. What is the current total annual production capacity for THAM-E API across all identified suppliers?

The current combined annual production capacity for THAM-E API from Manufacturer A, Manufacturer B, and Manufacturer C is 155 metric tons (50 + 75 + 30).

2. How does the geographical distribution of API suppliers for THAM-E impact supply chain resilience?

The geographical distribution across Germany, India, and China provides some resilience against regional disruptions. However, a concentration of capacity in any single region would increase vulnerability.

3. Are there any single-source dependencies for critical excipients used in THAM-E formulations?

Currently, no single excipient appears to be sourced from only one supplier, indicating a degree of diversification for these components. However, the breadth of supplier selection for each specific excipient needs continuous review.

4. What is the typical lead time for onboarding a new API supplier for THAM-E?

The typical lead time for onboarding a new API supplier can range from 12 to 24 months, encompassing process validation, quality agreements, regulatory documentation, and initial production runs.

5. How frequently are key CMO facilities for THAM-E inspected by regulatory authorities like the FDA or EMA?

Facilities of major CMOs like CMO Alpha, which serve FDA and EMA regulated markets, are typically inspected on a rolling basis, often with FDA inspections occurring every 2-3 years and EMA-related inspections on a similar cycle, depending on regulatory priorities.

Cited Sources

[1] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-research-and-development/good-manufacturing-practice [2] U.S. Food and Drug Administration. (n.d.). Inspections, Compliance, Enforcement, and Criminal Investigations. Retrieved from https://www.fda.gov/inspections-compliance-enforcement [3] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/regulation-prequalification/policy-guidance/good-manufacturing-practice [4] National Medical Products Administration. (n.d.). Regulatory Information. Retrieved from http://english.nmpa.gov.cn/ [5] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia